Arch Biopartners, Inc.

As of June 30, 2026, Arch Biopartners, Inc. carries a market capitalization of 53.67M, placing it among publicly traded companies globally. Its enterprise value stands at 56.26M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Arch Biopartners, Inc.'s next confirmed earnings release is scheduled for February 2, 2027.

As of June 30, 2026, Arch Biopartners, Inc. has 67.93M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Arch Biopartners, Inc. maintains a current ratio of 0.01, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -65.03, indicating conservative leverage, while an interest coverage ratio of -12.05 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -1,745.74, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Arch Biopartners, Inc.'s stock has declined approximately 5.43% over the past 52 weeks. The 50-day moving average sits at 0.94, while the 200-day moving average is 0.80.

Over the twelve months ended June 30, 2026, Arch Biopartners, Inc. generated - - in revenue and converted that into -2.83M in net income, yielding earnings per share of -0.04. EBITDA reached -2.83M, while operating income came in at -2.59M.

As of June 30, 2026, Arch Biopartners, Inc. holds 2,914.00 in cash and equivalents against 2.59M in total debt, resulting in a net debt position of 2.59M. Total book value stands at -3.99M, with working capital of -3.99M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -2.93, meaning Arch Biopartners, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Arch Biopartners, Inc.'s most recent stock split took place on November 25, 2003 with a 3:1 split ratio.

As of June 30, 2026, Arch Biopartners, Inc. has an Altman Z-Score of -1,108.03, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.